S772 Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S357-S358
10.14309/01.ajg.0000776620.39225.48